查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2088759

罕見疾病基因檢測市場：依檢測類型、技術、疾病、應用和最終用戶分類－2026-2032年全球市場預測

Rare Disease Genetic Testing Market by Test Type, Technology, Disease Indication, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，罕見疾病基因檢測市場規模將達到 53.9 億美元，年複合成長率為 17.00%。

主要市場統計數據
基準年 2025 17.9億美元
預計年份：2026年 20.9億美元
預測年份 2032 53.9億美元
複合年成長率 (%) 17.00%

罕見疾病基因檢測的引入

罕見疾病基因檢測正從專門的診斷工具轉變為精準醫療的基礎功能。根據公共衛生機構和罕見疾病組織統計，全球已發現超過1萬種罕見疾病，其中大多數具有遺傳因素，影響數億人。這導致臨床上對次世代定序、全EXOME定序、全基因測序、染色體微陣列分析、帶因者篩檢、新生兒篩檢和標靶分子診斷等技術的需求持續成長。

罕見疾病檢測的變革性變化

罕見疾病基因檢測領域正因高通量定序技術的快速普及以及從單基因檢測到更廣泛的基因panel檢測、EXOME定序和基因測序的轉變而改變。定序成本的降低、基於雲端的生物資訊學以及不斷擴展的變異資料庫正在提高診斷準確性，而ACMG、AMP、ClinGen和GA4GH等標準則促使檢測實驗室採用更一致的臨床解讀方法。

人工智慧（AI）的累積影響

人工智慧 (AI) 正在對罕見疾病基因檢測的整個價值鏈產生累積影響。 AI 驅動的表現型擷取技術能夠分析臨床記錄、影像報告、檢測結果和電子健康記錄，從而識別出原本可能被遺漏的症候群模式。機器學習工具透過結合基因組證據和遺傳模式、人群頻率、疾病資料庫、功能預測以及患者表現型數據，提高了突變優先排序的準確性。

全球市場主要區域趨勢

隨著中國、日本、韓國、澳洲和印度不斷擴大基因組定序能力、臨床研究網路和新生兒篩檢項目，亞太地區正成為罕見疾病基因檢測領域最具活力的地區之一。中國正在擴大定定序基礎設施並增加對精準醫療的投資，而日本則受惠於先進的臨床遺傳學和全民健保體系。韓國正在加強基因組醫學與數位醫療的融合，而澳洲則正在推行全國性的舉措。印度也面臨日益成長的需求，這主要得益於大規模的患者群體、人們對醫學遺傳學的認知不斷提高以及私人診斷服務的擴張。

策略市場准入的關鍵群體分析

在東協地區，新加坡、泰國、馬來西亞、印尼、越南和菲律賓正在投資精準醫療、數位醫療和專業醫療網路，提高了罕見疾病基因檢測的可及性。然而，由於保險報銷體係不均衡和臨床遺傳學專家短缺，基因檢測的可及性仍存在差距。在海灣合作理事會（GCC）國家，基因組醫學因其對預防醫學的高度重視、國家轉型議程以及遺傳疾病在特定人群中具有高度臨床意義而成為優先事項，並得到了國家基因組舉措和醫院主導的定序項目的支持。

各國對罕見疾病遺傳學的深入見解

憑藉先進的臨床檢查室、大學附屬醫療中心、孤兒藥研發以及EXOME基因測序的廣泛應用，美國在罕見疾病基因檢測領域處於創新領先地位。加拿大則著重於公共醫療體系、省級遺傳學計畫、新生兒篩檢和科研合作。墨西哥正透過公共和私營醫療管道擴大分子診斷的覆蓋範圍。巴西由於其龐大的人口基數、完善的公共衛生基礎設施、針對罕見疾病的政策舉措以及不斷擴展的臨床遺傳學網路，在罕見疾病領域尤為重要。

為行業領導者提供的實用建議

產業領導者應優先考慮與高發生性罕見疾病類別相符的、經臨床驗證的檢測項目，這些類別包括神經病學、代謝性疾病、免疫學、眼科學、遺傳性心血管疾病、檢驗相關遺傳症候群以及兒童遺傳學。實驗室和診斷服務提供者可以透過快速結果報告、透明的變異分類、定期複檢、遺傳諮詢支援、可靠的檢體運輸以及簡化的醫生申請檢測流程來脫穎而出。

調查方法和證據

這份執行調查方法基於一種三角測量方法，整合了同行評審的醫學文獻、公共衛生資源、監管資料資料庫、臨床指南庫、罕見疾病登記庫、檢查室檢驗框架和已驗證的基因組知識庫。所考慮的資訊來源包括已建立的基因組學標準、衛生當局出版刊物、孤兒藥和臨床試驗資料庫、新生兒篩檢參考資料以及經認證的罕見疾病資源，例如 OMIM、Orphanet、ClinVar、ClinGen 和 GeneReviews。

結論：罕見疾病檢測的未來

隨著定序、人工智慧分析、臨床遺傳學和精準醫療的融合，罕見疾病基因檢測正進入一個影響深遠的階段。提供大規模、精準的分子診斷能力在患者照護、臨床試驗招募、孤兒藥研發、新生兒篩檢現代化以及醫療體系轉型中發揮核心作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 罕見疾病基因檢測市場：依檢測類型分類

  • EXOME定序
    • 臨床EXOME
    • 用於研究的EXOME
  • 基因測序
    • 標靶基因組分析
    • 全基因組
  • 面板檢查
    • 癌症小組
    • 心血管小組
    • 神經系統面板
  • 單基因檢測

第8章：罕見疾病基因檢測市場：依技術分類

  • 微陣列
  • 次世代定序
    • 連接定序
    • 合成定定序
  • 聚合酵素鏈鎖反應
    • 數位PCR
    • 定量PCR

第9章：罕見疾病基因檢測市場：依疾病指徵分類

  • 血液疾病
  • 代謝性疾病
    • 酵素缺乏
    • 粒線體疾病
  • 神經肌肉疾病
  • 腫瘤學

第10章：罕見疾病基因檢測市場：依應用領域分類

  • 職業篩檢
  • 診斷
  • 新生兒篩檢
  • 產前篩檢
    • 侵入性
    • 非侵入性
  • 出於研究目的

第11章：罕見疾病基因檢測市場：依最終用戶分類

  • 診斷檢查室
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究機構
  • 專科診所

第12章：罕見疾病基因檢測市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：罕見疾病基因檢測市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 罕見疾病基因檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Ambry Genetics Corporation
  • Arup Laboratories
  • Caris Life Sciences
  • Centogene NV
  • Color Health, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • GeneDx, LLC
  • Genomelink, Inc.
  • Helix OpCo, LLC
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Invitae Corporation
  • Laboratory Corporation Of America Holdings
  • Macrogen, Inc.
  • Myriad Genetics, Inc.
  • Nonacus Limited
  • OPKO Health, Inc.
  • PerkinElmer Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Realm IDX, Inc.
  • Sanofi SA
  • The Cooper Companies, Inc.
  • Thermo Fisher Scientific Inc.
  • Variantyx, Inc.
Product Code: MRR-B9334AD6C623

The Rare Disease Genetic Testing Market is projected to grow by USD 5.39 billion at a CAGR of 17.00% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.79 billion
Estimated Year [2026] USD 2.09 billion
Forecast Year [2032] USD 5.39 billion
CAGR (%) 17.00%

Rare Disease Genetic Testing Introduction

Rare disease genetic testing is moving from a specialized diagnostic tool to a foundational capability in precision medicine. Public health and rare disease organizations estimate that more than 10,000 rare diseases have been identified worldwide, most have a genetic component, and collectively they affect hundreds of millions of people. This creates sustained clinical demand for next-generation sequencing, whole exome sequencing, whole genome sequencing, chromosomal microarray analysis, carrier screening, newborn screening, and targeted molecular diagnostics.

The sector is being shaped by clinical urgency: patients often experience a multiyear diagnostic odyssey before receiving a molecular diagnosis. Genetic testing can shorten that journey, guide therapy selection, inform family planning, improve clinical trial matching, and support the development of orphan drugs, gene therapies, and RNA-based therapeutics. As evidence standards mature, industry participants are differentiating on analytical validity, clinical utility, turnaround time, variant interpretation quality, genetic counseling integration, reimbursement support, and global data interoperability.

Transformative Shifts in Rare Disease Testing

The rare disease genetic testing landscape is being transformed by rapid adoption of high-throughput sequencing and a shift from single-gene testing toward broader panels, exome sequencing, and genome sequencing. Lower sequencing costs, cloud-based bioinformatics, and expanding variant databases are improving diagnostic yield, while standards from ACMG, AMP, ClinGen, and GA4GH are helping laboratories produce more consistent clinical interpretations.

Another major shift is the convergence of diagnostics, therapeutics, and real-world evidence. As gene therapies, enzyme replacement therapies, RNA-based medicines, and targeted orphan drugs expand, genetic testing is becoming essential for treatment eligibility, patient stratification, and post-diagnosis care pathways. Health systems are also investing in newborn screening modernization, population genomics, electronic health record integration, and secure data exchange, creating a more connected ecosystem for rare disease diagnosis and long-term management.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating a cumulative impact across the rare disease genetic testing value chain. AI-enabled phenotype extraction can review clinical notes, imaging reports, laboratory results, and electronic health records to identify syndromic patterns that may otherwise be missed. Machine learning tools are also improving variant prioritization by combining genomic evidence with inheritance patterns, population frequency, disease databases, functional predictions, and patient phenotype data.

The strongest opportunity is not replacing clinical geneticists, but increasing their productivity, consistency, and ability to revisit unsolved cases as knowledge evolves. AI can reduce manual curation burden, accelerate periodic reanalysis, support automated triage for high-priority variants, and improve clinical trial matching for genetically defined rare diseases. Responsible deployment requires transparent model validation, bias monitoring, human expert review, cybersecurity controls, and compliance with evolving regulatory and data protection frameworks, including the EU AI Act, FDA software guidance, and privacy requirements for sensitive genomic information.

Key Regional Insights Across Global Markets

Asia-Pacific is becoming one of the most dynamic regions for rare disease genetic testing as China, Japan, South Korea, Australia, and India expand genomics capacity, clinical research networks, and newborn screening programs. China has scaled sequencing infrastructure and precision medicine investment, Japan benefits from advanced clinical genetics and universal health coverage, South Korea is strengthening genomic medicine and digital health integration, Australia has nationally coordinated genomics initiatives, and India is seeing rising demand driven by large patient populations, medical genetics awareness, and expanding private diagnostics.

North America remains a global innovation hub, led by the United States and Canada, where accredited laboratories, regulatory oversight, academic medical centers, payer evidence frameworks, and orphan drug development support strong clinical adoption. Europe shows deep institutional strength through national genomic medicine programs, rare disease reference networks, and the European Union's focus on cross-border health data and harmonized evidence generation. Latin America is progressing through Brazil, Mexico, and regional specialty centers, although access remains shaped by reimbursement gaps and uneven laboratory capacity. The Middle East is gaining momentum through national genome programs, tertiary hospital sequencing initiatives, and preventive health policy, while Africa represents a high-need region where improved local laboratory infrastructure, workforce development, ethical data governance, and partnerships are critical to reducing sample logistics barriers and diagnostic delays.

Key Group Insights for Strategic Market Entry

Within ASEAN, rare disease genetic testing adoption is rising as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines invest in precision medicine, digital health, and specialist care networks, though uneven reimbursement and limited clinical genetics workforce capacity continue to fragment access. GCC countries are prioritizing genomics due to strong policy interest in preventive health, national transformation agendas, and the higher clinical relevance of inherited disorders in some populations, supported by national genome initiatives and hospital-led sequencing programs.

The European Union is advancing rare disease diagnosis through European Reference Networks, data harmonization, cross-border collaboration, and health technology assessment alignment. BRICS markets combine large unmet diagnostic need with expanding sequencing capabilities, public health modernization, and growing interest in local genomic data resources. G7 countries continue to set the pace in clinical evidence standards, reimbursement design, regulatory quality, newborn screening modernization, and precision medicine infrastructure. NATO members overlap with many advanced health systems where secure health data infrastructure, resilient supply chains, cyber-protected laboratory networks, and reliable access to critical molecular diagnostics are increasingly treated as strategic healthcare priorities.

Key Country Insights in Rare Disease Genetics

The United States leads in rare disease genetic testing innovation through advanced clinical laboratories, academic medical centers, orphan drug development, and broad use of exome and genome sequencing, while Canada emphasizes publicly funded health systems, provincial genetics programs, newborn screening, and research collaboration. Mexico is expanding molecular diagnostics access through public and private healthcare channels, and Brazil shows particular relevance due to its large population, public health infrastructure, rare disease policy activity, and growing clinical genetics networks.

In Europe, the United Kingdom is anchored by the NHS Genomic Medicine Service and national sequencing pathways, Germany and France support strong clinical laboratory systems and reimbursement structures, Italy and Spain maintain active rare disease networks and reference centers, and Russia has scientific capacity but faces access, funding, and geopolitical constraints. In Asia-Pacific, China, India, Japan, Australia, and South Korea are critical markets for rare disease genetics: China and India offer scale and expanding diagnostic capacity, Japan and South Korea offer advanced medical technology adoption and specialist care, and Australia provides well-coordinated public genomics programs that support evidence-based clinical implementation.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated test menus aligned with high-burden rare disease categories, including neurology, metabolic disorders, immunology, ophthalmology, inherited cardiovascular conditions, oncology-related hereditary syndromes, and pediatric genetics. Laboratories and diagnostic providers can differentiate through faster turnaround time, transparent variant classification, periodic reanalysis, genetic counseling support, sample logistics reliability, and seamless physician ordering workflows.

Strategic partnerships are essential. Organizations should collaborate with hospitals, patient advocacy groups, biopharma sponsors, newborn screening programs, public health agencies, and health technology assessment bodies to generate evidence that supports reimbursement and clinical adoption. Leaders should also invest in AI governance, interoperable data architecture, ancestry-diverse variant databases, secure cloud bioinformatics, and privacy-preserving data sharing to improve diagnostic equity, reduce false negatives in underrepresented populations, and strengthen long-term trust in rare disease genetic testing.

Research Methodology and Evidence Base

This executive analysis is built on a triangulated research methodology that integrates peer-reviewed medical literature, public health resources, regulatory databases, clinical guideline repositories, rare disease registries, laboratory accreditation frameworks, and validated genomic knowledge bases. Sources considered include established genomics standards, health authority publications, orphan drug and clinical trial databases, newborn screening references, and recognized rare disease resources such as OMIM, Orphanet, ClinVar, ClinGen, and GeneReviews.

Market interpretation is validated through cross-comparison of technology adoption patterns, reimbursement signals, national genomics initiatives, clinical utility evidence, regulatory requirements, and regional healthcare infrastructure. The methodology emphasizes data consistency, source credibility, and conservative interpretation, avoiding unsupported sizing or forecasting claims while focusing on verified drivers, barriers, and strategic implications for rare disease genetic testing stakeholders.

Conclusion: Future of Rare Disease Testing

Rare disease genetic testing is entering a high-impact phase as sequencing, AI-enabled interpretation, clinical genetics, and precision therapeutics converge. The ability to deliver accurate molecular diagnosis at scale is becoming central to patient care, clinical trial recruitment, orphan drug development, newborn screening modernization, and health system transformation.

Organizations that combine scientific rigor with accessible testing models will be best positioned to lead. Success will depend on diagnostic quality, reimbursement evidence, ethical data use, ancestry-inclusive databases, global partnerships, and continuous reanalysis as medical knowledge evolves. For industry leaders, the opportunity is clear: rare disease genetic testing is no longer only a diagnostic category, but a strategic infrastructure layer for precision medicine.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Rare Disease Genetic Testing Market, by Test Type

  • 7.1. Exome Sequencing
    • 7.1.1. Clinical Exome
    • 7.1.2. Research Exome
  • 7.2. Genome Sequencing
    • 7.2.1. Targeted Genome
    • 7.2.2. Whole Genome
  • 7.3. Panel Test
    • 7.3.1. Cancer Panels
    • 7.3.2. Cardiovascular Panels
    • 7.3.3. Neurological Panels
  • 7.4. Single Gene Test

8. Rare Disease Genetic Testing Market, by Technology

  • 8.1. Microarray
  • 8.2. Next Generation Sequencing
    • 8.2.1. Sequencing By Ligation
    • 8.2.2. Sequencing By Synthesis
  • 8.3. Polymerase Chain Reaction
    • 8.3.1. Digital PCR
    • 8.3.2. Quantitative PCR

9. Rare Disease Genetic Testing Market, by Disease Indication

  • 9.1. Hematological Disorders
  • 9.2. Metabolic Disorders
    • 9.2.1. Enzyme Deficiencies
    • 9.2.2. Mitochondrial Disorders
  • 9.3. Neuromuscular Disorders
  • 9.4. Oncology

10. Rare Disease Genetic Testing Market, by Application

  • 10.1. Carrier Screening
  • 10.2. Diagnostics
  • 10.3. Newborn Screening
  • 10.4. Prenatal Screening
    • 10.4.1. Invasive
    • 10.4.2. Non Invasive
  • 10.5. Research Applications

11. Rare Disease Genetic Testing Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Research Institutions
  • 11.4. Specialty Clinics

12. Rare Disease Genetic Testing Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Rare Disease Genetic Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Rare Disease Genetic Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Ambry Genetics Corporation
  • 16.2. Arup Laboratories
  • 16.3. Caris Life Sciences
  • 16.4. Centogene N.V.
  • 16.5. Color Health, Inc.
  • 16.6. F. Hoffmann-La Roche Ltd.
  • 16.7. Fulgent Genetics, Inc.
  • 16.8. GeneDx, LLC
  • 16.9. Genomelink, Inc.
  • 16.10. Helix OpCo, LLC
  • 16.11. Illumina, Inc.
  • 16.12. Integrated DNA Technologies, Inc.
  • 16.13. Invitae Corporation
  • 16.14. Laboratory Corporation Of America Holdings
  • 16.15. Macrogen, Inc.
  • 16.16. Myriad Genetics, Inc.
  • 16.17. Nonacus Limited
  • 16.18. OPKO Health, Inc.
  • 16.19. PerkinElmer Inc.
  • 16.20. QIAGEN N.V.
  • 16.21. Quest Diagnostics Incorporated
  • 16.22. Realm IDX, Inc.
  • 16.23. Sanofi S.A.
  • 16.24. The Cooper Companies, Inc.
  • 16.25. Thermo Fisher Scientific Inc.
  • 16.26. Variantyx, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RARE DISEASE GENETIC TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL RARE DISEASE GENETIC TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL RARE DISEASE GENETIC TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL RARE DISEASE GENETIC TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL RARE DISEASE GENETIC TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL RARE DISEASE GENETIC TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EXOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EXOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EXOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CLINICAL EXOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CLINICAL EXOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL EXOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RESEARCH EXOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RESEARCH EXOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RESEARCH EXOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED GENOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED GENOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED GENOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL WHOLE GENOME MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL WHOLE GENOME MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL WHOLE GENOME MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PANEL TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PANEL TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PANEL TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER PANELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER PANELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER PANELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIOVASCULAR PANELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARDIOVASCULAR PANELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIOVASCULAR PANELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROLOGICAL PANELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROLOGICAL PANELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROLOGICAL PANELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SINGLE GENE TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SINGLE GENE TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SINGLE GENE TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SEQUENCING BY LIGATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SEQUENCING BY LIGATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SEQUENCING BY LIGATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SEQUENCING BY SYNTHESIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SEQUENCING BY SYNTHESIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SEQUENCING BY SYNTHESIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL QUANTITATIVE PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL QUANTITATIVE PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL QUANTITATIVE PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HEMATOLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HEMATOLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEMATOLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENZYME DEFICIENCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENZYME DEFICIENCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENZYME DEFICIENCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MITOCHONDRIAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MITOCHONDRIAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MITOCHONDRIAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROMUSCULAR DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROMUSCULAR DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROMUSCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CARRIER SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARRIER SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CARRIER SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PRENATAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PRENATAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PRENATAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INVASIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INVASIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INVASIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NON INVASIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NON INVASIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NON INVASIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 221. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 222. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 223. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 225. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 228. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 230. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GCC RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 263. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 264. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 265. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 267. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 268. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 269. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 270. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 271. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 272. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. G7 RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 277. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 278. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 279. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 281. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 282. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 283. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 284. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 286. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. NATO RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL RARE DISEASE GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 303. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 306. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 307. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 308. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 317. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 320. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 321. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 322. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 324. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 326. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY METABOLIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 327. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 328. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY PRENATAL SCREENING, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 330. MEXICO RARE DISEASE GENETIC TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 331. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 332. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY EXOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 334. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY GENOME SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 335. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY PANEL TEST, 2018-2032 (USD MILLION)
  • TABLE 336. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 337. BRAZIL RARE DISEASE GENETIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 338. BRAZIL RARE DISEASE GE